XML 72 R38.htm IDEA: XBRL DOCUMENT
v3.19.2

Revenues (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 5,685 | $ 5,648 | $ 10,966 | $ 10,736
Revenues | 5,685 | 5,648 | 10,966 | 10,736
U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 4,073 | 4,083 | 7,891 | 7,630
Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 1,099 | 1,084 | 2,037 | 2,141
Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 513 | 481 | 1,038 | 965
Atripla |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 152 | 349 | 323 | 663
Atripla | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 122 | 274 | 255 | 502
Atripla | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 26 | 39 | 42 | 90
Atripla | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 4 | 36 | 26 | 71
Biktarvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 1,116 | 185 | 1,909 | 220
Biktarvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 1,023 | 183 | 1,762 | 218
Biktarvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 73 | 2 | 121 | 2
Biktarvy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 20 | 0 | 26 | 0
Complera/Eviplera |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 123 | 199 | 238 | 389
Complera/Eviplera | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 42 | 82 | 86 | 149
Complera/Eviplera | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 72 | 103 | 134 | 212
Complera/Eviplera | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 9 | 14 | 18 | 28
Descovy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 358 | 403 | 700 | 764
Descovy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 246 | 311 | 479 | 585
Descovy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 69 | 78 | 137 | 153
Descovy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 43 | 14 | 84 | 26
Genvoya |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 980 | 1,160 | 1,995 | 2,242
Genvoya | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 733 | 904 | 1,461 | 1,757
Genvoya | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 177 | 207 | 370 | 393
Genvoya | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 70 | 49 | 164 | 92
Odefsey |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 387 | 385 | 784 | 727
Odefsey | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 266 | 303 | 548 | 582
Odefsey | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 111 | 77 | 217 | 135
Odefsey | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 10 | 5 | 19 | 10
Stribild |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 108 | 187 | 204 | 361
Stribild | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 78 | 144 | 145 | 277
Stribild | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 24 | 34 | 42 | 63
Stribild | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 6 | 9 | 17 | 21
Truvada |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 718 | 765 | 1,324 | 1,417
Truvada | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 657 | 649 | 1,208 | 1,156
Truvada | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 41 | 86 | 74 | 183
Truvada | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 20 | 30 | 42 | 78
Other HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 15 | 19 | 32 | 32
Other HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 9 | 11 | 20 | 20
Other HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 1 | 3 | 2 | 4
Other HIV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 5 | 5 | 10 | 8
Revenue share - Symtuza |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 84 | 13 | 150 | 20
Revenue share - Symtuza | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 55 | 0 | 97 | 0
Revenue share - Symtuza | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 29 | 13 | 53 | 20
Revenue share - Symtuza | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
AmBisome |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 105 | 103 | 198 | 210
AmBisome | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 10 | 14 | 18 | 31
AmBisome | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 60 | 55 | 117 | 111
AmBisome | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 35 | 34 | 63 | 68
Ledipasvir/Sofosbuvir |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 193 | 331 | 418 | 679
Ledipasvir/Sofosbuvir | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 86 | 230 | 203 | 464
Ledipasvir/Sofosbuvir | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 22 | 22 | 49 | 78
Ledipasvir/Sofosbuvir | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 85 | 79 | 166 | 137
Letairis |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 204 | 244 | 401 | 448
Letairis | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 204 | 244 | 401 | 448
Letairis | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Letairis | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Ranexa |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 19 | 208 | 174 | 403
Ranexa | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 19 | 208 | 174 | 403
Ranexa | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Ranexa | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Sofosbuvir/Velpatasvir |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 493 | 500 | 984 | 1,036
Sofosbuvir/Velpatasvir | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 219 | 239 | 449 | 508
Sofosbuvir/Velpatasvir | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 156 | 168 | 310 | 366
Sofosbuvir/Velpatasvir | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 118 | 93 | 225 | 162
Vemlidy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 116 | 76 | 217 | 134
Vemlidy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 71 | 59 | 136 | 106
Vemlidy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 5 | 3 | 9 | 6
Vemlidy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 40 | 14 | 72 | 22
Viread |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 75 | 82 | 147 | 179
Viread | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 9 | 16 | 21 | 23
Viread | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 28 | 32 | 42 | 62
Viread | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 38 | 34 | 84 | 94
Vosevi |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 75 | 109 | 138 | 216
Vosevi | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 53 | 86 | 98 | 172
Vosevi | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 15 | 20 | 31 | 36
Vosevi | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 7 | 3 | 9 | 8
Yescarta |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 120 | 68 | 216 | 108
Yescarta | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 99 | 68 | 189 | 108
Yescarta | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 21 | 0 | 27 | 0
Yescarta | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Zydelig |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 26 | 39 | 53 | 72
Zydelig | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 12 | 17 | 23 | 31
Zydelig | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 14 | 22 | 29 | 40
Zydelig | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 1 | 1
Other(3) |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 140 | 115 | 202 | 221
Other(3) | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 41 | 27 | 77 | 56
Other(3) | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 97 | 41 | 117 | 56
Other(3) | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 2 | 47 | 8 | 109
Product sales |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 5,607 | 5,540 | 10,807 | 10,541
Product sales | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 4,054 | 4,069 | 7,850 | 7,596
Product sales | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 1,041 | 1,005 | 1,923 | 2,010
Product sales | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 512 | 466 | 1,034 | 935
Royalty, contract and other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 78 | 108 | 159 | 195
Revenues | 78 | 108 | 159 | 195
Royalty, contract and other revenues | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 19 | 14 | 41 | 34
Royalty, contract and other revenues | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 58 | 79 | 114 | 131
Royalty, contract and other revenues | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 1 | $ 15 | $ 4 | $ 30

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsStribildMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsVireadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsVoseviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |